insulin

Pharmalot By Ed Silverman

Pharmalittle: FDA OKs new type of diabetes drug from Lilly; Early-stage biotechs are juicy targets for M&A surge

Biotech By Damian Garde

Seagen CEO resigns after arrest on domestic assault charges

First Opinion By Shoshana Ungerleider

One million reasons to reimagine end-of-life care

Color Code By Nicholas St. Fleur

A ‘city on fire’: How Miami shaped a disputed diagnosis used to justify deaths in police custody

Health By Helen Branswell

Puzzling pediatric hepatitis cases echo an earlier mysterious illness

Biotech By Kate Sheridan

When biotech acquisitions spike, early-stage startups are prime targets, analysis shows

Biotech By Matthew Herper

FDA approves Lilly diabetes drug that analysts expect to be a big seller

Exclusive By Nicholas Florko

Senate FDA legislation will include dietary supplement, cosmetic reforms